Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics.
2-NBDG, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose
ABCG2, ATP-binding cassette subfamily G member 2
ACN, acetonitrile
Au/Uv, absorbance unit of ultraviolet-visible spectroscopy
BCRP, breast cancer resistant protein
BERA, bioengineered miRNA agent
Bioengineered RNA
CI, combination index
CPT, cisplatin
Cancer
Chemosensitivity
DOX, doxorubicin
E. coli, Escherichia coli
ESI, electrospray ionization
FPLC, fast protein liquid chromatography
Fa, fraction affected
GLUT1
GLUT1, glucose transporter protein type 1
HCC, hepatocellular carcinoma
HPLC, high-performance liquid chromatography
IS, internal standard
KRB, Krebs–Ringer bicarbonate
LAT1
LAT1, large neutral amino acid transporter 1
LC–MS/MS, liquid chromatography–tandem mass spectroscopy
MCT4, monocarboxylate transporter 4
MRE, miRNA response elements
MRM, multiple reaction monitoring
MiR-328
OS, osteosarcoma
PAGE, polyacrylamide gel electrophoresis
PTEN, phosphatase and tensin homolog
PVDF, Polyvinylidene fluoride
RAGE, receptor for advanced glycosylation end products
RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction
SLC2A1, 7A5, 16A3, solute carrier family 2 member 1, family 7 member 5, family 16 member 3
WT, wild type
hBERA, humanized bioengineered miRNA agent
hsa, Homo sapiens
htRNASer, human seryl-tRNA
mTOR, mammalian target of rapamycin
miR or miRNA, microRNA
ncRNA, noncoding RNAs
nt, nucleotide
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
26
06
2019
revised:
16
08
2019
accepted:
31
10
2019
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
30
1
2020
Statut:
ppublish
Résumé
MicroRNAs (miRNAs or miRs) are small noncoding RNAs derived from genome to control target gene expression. Recently we have developed a novel platform permitting high-yield production of bioengineered miRNA agents (BERA). This study is to produce and utilize novel fully-humanized BERA/miR-328-3p molecule (hBERA/miR-328) to delineate the role of miR-328-3p in controlling nutrient uptake essential for cell metabolism. We first demonstrated successful high-level expression of hBERA/miR-328 in bacteria and purification to high degree of homogeneity (>98%). Biologic miR-328-3p prodrug was selectively processed to miR-328-3p to suppress the growth of highly-proliferative human osteosarcoma (OS) cells. Besides glucose transporter protein type 1, gene symbol solute carrier family 2 member 1 (GLUT1/
Identifiants
pubmed: 31993313
doi: 10.1016/j.apsb.2019.11.001
pii: S2211-3835(19)30908-6
pmc: PMC6976971
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-170Subventions
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA225958
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM113888
Pays : United States
Informations de copyright
© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Références
Pediatr Blood Cancer. 2013 Jun;60(6):1009-15
pubmed: 23255238
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:72-81
pubmed: 31177050
Expert Opin Drug Metab Toxicol. 2018 May;14(5):493-504
pubmed: 29718737
Oncol Rep. 2018 Jun;39(6):2906-2914
pubmed: 29620238
J Clin Oncol. 1994 Dec;12(12):2614-20
pubmed: 7989936
Acta Pharm Sin B. 2017 Jan;7(1):38-51
pubmed: 28119807
Drug Metab Dispos. 2016 Mar;44(3):308-19
pubmed: 26566807
Drug Metab Dispos. 2015 Jul;43(7):1129-36
pubmed: 25934574
Annu Rev Genomics Hum Genet. 2007;8:215-39
pubmed: 17506656
Biochim Biophys Acta. 2010 Dec;1806(2):200-7
pubmed: 20637263
Oncotarget. 2017 May 9;8(19):30742-30755
pubmed: 28415566
Oncogene. 2011 Jan 20;30(3):253-64
pubmed: 20972457
Drug Metab Dispos. 2014 Nov;42(11):1791-5
pubmed: 25161167
Biochim Biophys Acta. 2013 Apr;1835(2):164-9
pubmed: 23266512
Drug Metab Dispos. 2013 Oct;41(10):1744-51
pubmed: 23686318
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6324-6332
pubmed: 30338800
Cancer Lett. 2010 Dec 8;298(2):176-85
pubmed: 20678861
Cancer Lett. 2019 Feb 1;442:82-90
pubmed: 30389433
Genomics. 2015 May;105(5-6):275-81
pubmed: 25773945
Mol Cell. 2010 Oct 22;40(2):310-22
pubmed: 20965424
Biochem Pharmacol. 2015 Dec 15;98(4):602-13
pubmed: 26518752
Int J Mol Sci. 2019 May 16;20(10):null
pubmed: 31100853
Oncotarget. 2016 Jul 19;7(29):45547-45561
pubmed: 27322206
Appl Microbiol Biotechnol. 2019 Aug;103(15):6107-6117
pubmed: 31187211
Bioengineered. 2016 Nov;7(6):411-417
pubmed: 27415469
Sci Rep. 2016 May 24;6:26611
pubmed: 27216562
Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):186-97
pubmed: 26763749
Cancer Cell Int. 2019 Apr 23;19:104
pubmed: 31043859
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
Cancer Metastasis Rev. 2009 Jun;28(1-2):247-63
pubmed: 19214708
Mol Pharmacol. 2009 Jun;75(6):1374-9
pubmed: 19270061
Clin Transl Oncol. 2018 Sep;20(9):1161-1167
pubmed: 29374351
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Paediatr Drugs. 2015 Aug;17(4):257-71
pubmed: 26002157
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
Cancer Res. 2010 Sep 15;70(18):7027-30
pubmed: 20807816
Oncol Rep. 2018 Feb;39(2):545-553
pubmed: 29207178
Leuk Res. 2016 Feb;41:103-10
pubmed: 26790725
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Acta Pharm Sin B. 2019 May;9(3):639-647
pubmed: 31193825
Onco Targets Ther. 2015 Oct 28;8:3159-67
pubmed: 26604785
Nucleic Acids Res. 2015 Apr 20;43(7):3857-69
pubmed: 25800741
J Pharmacol Exp Ther. 2018 Jun;365(3):494-506
pubmed: 29602831
Nat Rev Cancer. 2016 Oct;16(10):619-34
pubmed: 27492215
Cancer Cell. 2008 Jun;13(6):472-82
pubmed: 18538731
Sci Rep. 2016 Aug 17;6:31651
pubmed: 27530148
J Pharmacol Exp Ther. 2015 Aug;354(2):131-41
pubmed: 26022002
Cancer Res. 2015 May 1;75(9):1782-8
pubmed: 25855379